AP Biosciences Inc (TPEX:6945)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
55.90
+1.40 (2.57%)
Jul 17, 2025, 1:42 PM CST
-0.18%
Market Cap4.76B
Revenue (ttm)n/a
Net Income (ttm)-422.75M
Shares Out85.11M
EPS (ttm)-5.61
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume136,053
Average Volume62,925
Open53.20
Previous Close54.50
Day's Range53.20 - 55.90
52-Week Range36.30 - 59.90
Beta0.59
RSI56.08
Earnings DateAug 8, 2025

About AP Biosciences

AP Biosciences Inc, a clinical-stage biopharmaceutical company, researches and develops bispecific antibody drugs for unmet medical needs. It develops IBI302 that is in phase III clinical trials for the treatment of neovascular age-related macular degeneration; AP505 that is in phase I clinical trials for treating solid tumors; AP203 that is in phase I clinical trial for non-small cell lung cancer, head and neck squamous cell carcinoma, and esophageal squamous-cell carcinomas; AP402, which is in in the pre-clinical research phase for breast ca... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2013
Employees 37
Stock Exchange Taipei Exchange
Ticker Symbol 6945
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.